menu
    • menu

    Find Lenacapavir manufacturers, exporters & distributors on PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    0

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    0

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 0

    MARKET PLACE

    0

    API

    0

    FDF

    10INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    2

    FDF Dossiers

    FDF Dossiers

    2

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    29DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    10

    US Patents

    2

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    1

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    37

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    NA

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Gs-6207, 2189684-44-2, Gs-hiv, Gs-ca2, Gs-ca-2, Lenacapavir [usan]
    Molecular Formula
    C39H32ClF10N7O5S2
    Molecular Weight
    968.3  g/mol
    InChI Key
    BRYXUCLEHAUSDY-WEWMWRJBSA-N
    FDA UNII
    A9A0O6FB4H
    Lenacapavir
    Lenacapavir is under investigation in clinical trial NCT04150068 (Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance).
    1 2D Structure

    Lenacapavir

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[(1S)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide
    2.1.2 InChI
    InChI=1S/C39H32ClF10N7O5S2/c1-36(2,63(3,59)60)10-9-21-5-6-22(23-7-8-26(40)30-32(23)57(17-37(43,44)45)54-35(30)55-64(4,61)62)31(51-21)27(13-18-11-19(41)14-20(42)12-18)52-28(58)16-56-34-29(33(53-56)39(48,49)50)24-15-25(24)38(34,46)47/h5-8,11-12,14,24-25,27H,13,15-17H2,1-4H3,(H,52,58)(H,54,55)/t24-,25+,27-/m0/s1
    2.1.3 InChI Key
    BRYXUCLEHAUSDY-WEWMWRJBSA-N
    2.1.4 Canonical SMILES
    CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)(F)F)NS(=O)(=O)C)C(CC4=CC(=CC(=C4)F)F)NC(=O)CN5C6=C(C7CC7C6(F)F)C(=N5)C(F)(F)F)S(=O)(=O)C
    2.1.5 Isomeric SMILES
    CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)(F)F)NS(=O)(=O)C)[C@H](CC4=CC(=CC(=C4)F)F)NC(=O)CN5C6=C([C@H]7C[C@H]7C6(F)F)C(=N5)C(F)(F)F)S(=O)(=O)C
    2.2 Other Identifiers
    2.2.1 UNII
    A9A0O6FB4H
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Gs-ca1

    2.3.2 Depositor-Supplied Synonyms

    1. Gs-6207

    2. 2189684-44-2

    3. Gs-hiv

    4. Gs-ca2

    5. Gs-ca-2

    6. Lenacapavir [usan]

    7. Gs-ca1

    8. A9a0o6fb4h

    9. Gs-714207

    10. Gs6207

    11. N-[(1s)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2s,4r)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide

    12. N-((s)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1h-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bs,4ar)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1h-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

    13. N-[(1s)-1-(3-{4-chloro-3-[(methylsulfonyl)amino]-1-(2,2,2-trifluoroethyl)-1h-indazol-7-yl}-6-[3-methyl-3-(methylsulfonyl)but-1-yn-1-yl]pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl]-2-[(3bs,4ar)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1h-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide

    14. Qng

    15. Lenacapavir [inn]

    16. Unii-a9a0o6fb4h

    17. Lenacapavir [who-dd]

    18. Chembl4594438

    19. Schembl19875642

    20. Gtpl11446

    21. Ex-a5518

    22. Who 11108

    23. At20076

    24. Hy-111964

    25. Cs-0094695

    26. 1h-cyclopropa(3,4)cyclopenta(1,2-c)pyrazole, N-((1s)-1-(3-(4-chloro-3-((methylsulfonyl)amino)-1-(2,2,2-trifluoroethyl)-1h-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)-1-butyn-1-yl)-2-pyridinyl)-2-(3,5-difluorophenyl)ethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, (3bs,4ar)-

    27. N-((1s)-1-(3-(4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)-1h-indazol-7-yl)-6-(3-(methanesulfonyl)-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5- Difluorophenyl)ethyl)-2-((3bs,4ar)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1h-cyclopropa(3,4)cyclopenta(1,2-c)pyrazol-1-yl)acetamide

    28. N-[(1s)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonyl-but-1-ynyl)-2-pyridyl]-2-(3,5-difluorophenyl)ethyl]-2-[difluoro(trifluoromethyl)[?]yl]acetamide

    2.4 Create Date
    2018-05-16
    3 Chemical and Physical Properties
    Molecular Weight 968.3 g/mol
    Molecular Formula C39H32ClF10N7O5S2
    XLogP36.4
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count19
    Rotatable Bond Count13
    Exact Mass967.1435188 g/mol
    Monoisotopic Mass967.1435188 g/mol
    Topological Polar Surface Area175 Ų
    Heavy Atom Count64
    Formal Charge0
    Complexity2040
    Isotope Atom Count0
    Defined Atom Stereocenter Count3
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of human immunodeficiency virus (HIV-1) infection

    * Sunlenca injection: , in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 and 5. 1).

    * Sunlenca tablet: , in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 and 5. 1).

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    J05AX

    J - Antiinfectives for systemic use

    J05 - Antivirals for systemic use

    J05A - Direct acting antivirals

    J05AX - Other antivirals

    J05AX31 - Lenacapavir

    NDC API

    read-more
    read-more

    01

    Gilead Alberta ULC

    U.S.A
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Gilead Alberta ULC

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    LENACAPAVIR SODIUM

    NDC Package Code : 54014-6902

    Start Marketing Date : 2022-12-22

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Yuhan Chemical Inc

    South Korea
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Yuhan Chemical Inc

    South Korea
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag South Korea
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    LENACAPAVIR

    NDC Package Code : 66721-830

    Start Marketing Date : 2022-08-17

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (20kg/20kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck-Gilead Oral Combo Suppresses HIV for 48 Weeks, Preps for Pivotal Program

    Details:

    MK-8591 (islatravir) is a non-nucleoside reverse transcriptase translocation inhibitor, which is being investigated in phase 2 for HIV-1 infection, in combination with lenacapavir.


    Lead Product(s): Islatravir,Lenacapavir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: MK-8591

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Merck & Co

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 21, 2024

    blank

    01

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Islatravir,Lenacapavir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Merck & Co

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Merck-Gilead Oral Combo Suppresses HIV for 48 Weeks, Preps for Pivotal Program

    Details : MK-8591 (islatravir) is a non-nucleoside reverse transcriptase translocation inhibitor, which is being investigated in phase 2 for HIV-1 infection, in combination with lenacapavir.

    Brand Name : MK-8591

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    October 21, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Gilead Partners with Six Generics For Lenacapavir Access in HIV Prevention

    Details:

    The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.


    Lead Product(s): Lenacapavir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Sunlenca

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Viatris

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement October 02, 2024

    blank

    02

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lenacapavir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Viatris

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Gilead Partners with Six Generics For Lenacapavir Access in HIV Prevention

    Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.

    Brand Name : Sunlenca

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Hetero Partners with Gilead To Expand HIV Drug Lenacapavir Access Globally

    Details:

    The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.


    Lead Product(s): Lenacapavir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Sunlenca

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Hetero

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement October 02, 2024

    blank

    03

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lenacapavir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Hetero

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Hetero Partners with Gilead To Expand HIV Drug Lenacapavir Access Globally

    Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.

    Brand Name : Sunlenca

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Dr. Reddy’s Partners with Gilead to Manufacture Lenacapavir in India and Beyond

    Details:

    The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.


    Lead Product(s): Lenacapavir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Sunlenca

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Dr. Reddy\'s Laboratories

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement October 02, 2024

    blank

    04

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lenacapavir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Dr. Reddy\'s Laboratories

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Dr. Reddy’s Partners with Gilead to Manufacture Lenacapavir in India and Beyond

    Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.

    Brand Name : Sunlenca

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Gilead Partners with Six Generic Makers to Expand HIV Prevention Access Globally

    Details:

    The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.


    Lead Product(s): Lenacapavir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Sunlenca

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Emcure Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement October 02, 2024

    blank

    05

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lenacapavir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Emcure Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Gilead Partners with Six Generic Makers to Expand HIV Prevention Access Globally

    Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.

    Brand Name : Sunlenca

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Gilead Partners with Six Generic Makers to Expand HIV Prevention Access Globally

    Details:

    The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.


    Lead Product(s): Lenacapavir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Sunlenca

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Eva Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement October 02, 2024

    blank

    06

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lenacapavir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Eva Pharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Gilead Partners with Six Generic Makers to Expand HIV Prevention Access Globally

    Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.

    Brand Name : Sunlenca

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Gilead Partners with Six Generic Makers to Expand HIV Prevention Access Globally

    Details:

    The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.


    Lead Product(s): Lenacapavir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Sunlenca

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Ferozsons Laboratories

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement October 02, 2024

    blank

    07

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lenacapavir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Ferozsons Laboratories

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Gilead Partners with Six Generic Makers to Expand HIV Prevention Access Globally

    Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.

    Brand Name : Sunlenca

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Gilead and Merck Announce Phase 2 Data for Islatravir and Lenacapavir Combination Regimen

    Details:

    MK-8591 (islatravir) is a non-nucleoside reverse transcriptase translocation inhibitor, which is being investigated in phase 2 for HIV-1 infection, in combination with lenacapavir.


    Lead Product(s): Islatravir,Lenacapavir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: MK-8591

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Merck & Co

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 06, 2024

    blank

    08

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Islatravir,Lenacapavir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Merck & Co

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Gilead and Merck Announce Phase 2 Data for Islatravir and Lenacapavir Combination Regimen

    Details : MK-8591 (islatravir) is a non-nucleoside reverse transcriptase translocation inhibitor, which is being investigated in phase 2 for HIV-1 infection, in combination with lenacapavir.

    Brand Name : MK-8591

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    March 06, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Gilead’s Innovative HIV Research Pipeline Aims to Address Unmet Needs and Advance Health

    Details:

    GS-9883 (bictegravir), an HIV type 1 integrase inhibitor in combination with GS-6207 (lenacapavir), a structural capsid protein inhibitor is being evaluated for the treatment of HIV-1-infection.


    Lead Product(s): Bictegravir,Lenacapavir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: GS-9883

    Study Phase: Phase II/ Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 05, 2024

    blank

    09

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bictegravir,Lenacapavir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Gilead’s Innovative HIV Research Pipeline Aims to Address Unmet Needs and Advance Health

    Details : GS-9883 (bictegravir), an HIV type 1 integrase inhibitor in combination with GS-6207 (lenacapavir), a structural capsid protein inhibitor is being evaluated for the treatment of HIV-1-infection.

    Brand Name : GS-9883

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    March 05, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

    Details:

    Sunlenca (lenacapavir) is a selective long-acting inhibitor of HIV-1 capsid function which inhibits HIV-1 replication by interfering with multiple essential steps of the viral lifecycle.


    Lead Product(s): Lenacapavir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Sunlenca

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 18, 2023

    blank

    10

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lenacapavir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as...

    Details : Sunlenca (lenacapavir) is a selective long-acting inhibitor of HIV-1 capsid function which inhibits HIV-1 replication by interfering with multiple essential steps of the viral lifecycle.

    Brand Name : Sunlenca

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    October 18, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    INTERMEDIATES SUPPLIERS

    read-more
    read-more

    01

    Shanghai Minbiotech

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    2-((3bS,4aR)-5,5-Difluoro-3-(trifluoromethyl)-3b,4...

    CAS Number : 1620056-83-8

    End Use API : Lenacapavir

    About The Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...

    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Shanghai Minbiotech

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    3-Methyl-3-(methylsulfonyl)but-1-yne

    CAS Number : 2109226-54-0

    End Use API : Lenacapavir

    About The Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...

    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Shanghai Minbiotech

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    tert-butylN-[(1S)-1-(3,6-dibromopyridin-2-yl)-2-(3...

    CAS Number : 1620056-47-4

    End Use API : Lenacapavir

    About The Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...

    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Shanghai Minbiotech

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    Carbamic acid, N-[(1S)-1-[3-bromo-6-[3-methyl-3-(...

    CAS Number : 2189684-54-4

    End Use API : Lenacapavir

    About The Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...

    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Shanghai Minbiotech

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    4-Chloro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan...

    CAS Number : 2189684-53-3

    End Use API : Lenacapavir

    About The Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...

    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Porton Pharma Solutions

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

    2-((3bS,4aR)-5,5-difluoro-3- (trifluoromethyl)-3b,...

    CAS Number : 1620056-83-8

    End Use API : Lenacapavir

    About The Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & ope...

    Porton Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    SCI Pharmtech

    Taiwan
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.

    Benzhydrylamine

    CAS Number : 91-00-9

    End Use API : Lenacapavir

    About The Company : SCI Pharmtech Inc. offers APIs, advanced intermediates, and custom products, focusing on quick development and cost-effective production. Our research labs, pil...

    SCI Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    SCI Pharmtech

    Taiwan
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.

    Benzhydrylamine

    CAS Number : 91-00-9

    End Use API : Lenacapavir

    About The Company : SCI Pharmtech Inc. offers APIs, advanced intermediates, and custom products, focusing on quick development and cost-effective production. Our research labs, pil...

    SCI Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Saptagir Laboratories

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Saptagir Laboratories

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    4-Chloro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan...

    CAS Number : 2189684-53-3

    End Use API : Lenacapavir

    About The Company : Saptagir Laboratories Private incorporated in 2016, is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) and Intermediates for a wide rang...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Saptagir Laboratories

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Saptagir Laboratories

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Tert-butyl (S)-[1-(3-bromo-6-[3-methyl-3-(methyl s...

    CAS Number : 2189684-54-4

    End Use API : Lenacapavir

    About The Company : Saptagir Laboratories Private incorporated in 2016, is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) and Intermediates for a wide rang...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Gilead Sciences

    U.S.A
    AES 2024
    Not Confirmed
    arrow

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    LENACAPAVIR SODIUM

    Brand Name : SUNLENCA

    Dosage Form : SOLUTION;SUBCUTANEOUS

    Dosage Strength : EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)

    Packaging :

    Approval Date : 2022-12-22

    Application Number : 215973

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Gilead Sciences

    U.S.A
    AES 2024
    Not Confirmed
    arrow

    Gilead Sciences

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    LENACAPAVIR SODIUM

    Brand Name : SUNLENCA

    Dosage Form : TABLET;ORAL

    Dosage Strength : EQ 300MG BASE

    Packaging :

    Approval Date : 2022-12-22

    Application Number : 215974

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    01

    GILEAD SCIENCES INC

    U.S.A
    AES 2024
    Not Confirmed
    arrow

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : Yes

    TE Code :

    LENACAPAVIR SODIUM

    Brand Name : SUNLENCA

    Dosage Form : SOLUTION;SUBCUTANEOUS

    Dosage Strength : EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)

    Approval Date : 2022-12-22

    Application Number : 215973

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    GILEAD SCIENCES INC

    U.S.A
    AES 2024
    Not Confirmed
    arrow

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : Yes

    TE Code :

    LENACAPAVIR SODIUM

    Brand Name : SUNLENCA

    Dosage Form : TABLET;ORAL

    Dosage Strength : EQ 300MG BASE

    Approval Date : 2022-12-22

    Application Number : 215974

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    STOCK RECAP #PipelineProspector

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    US Patents

    read-more
    read-more

    01

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    AES 2024
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2034-02-28

    LENACAPAVIR SODIUM

    US Patent Number : 9951043

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 215973

    Patent Use Code : U-3507

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2034-02-28

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    AES 2024
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2034-02-28

    LENACAPAVIR SODIUM

    US Patent Number : 9951043

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 215974

    Patent Use Code : U-3507

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2034-02-28

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    AES 2024
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2037-08-17

    LENACAPAVIR SODIUM

    US Patent Number : 10654827

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 215974

    Patent Use Code : U-3507

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2037-08-17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    AES 2024
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2038-08-16

    LENACAPAVIR SODIUM

    US Patent Number : 11267799

    Drug Substance Claim : Y

    Drug Product Claim :

    Application Number : 215974

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2038-08-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    AES 2024
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2037-08-17

    LENACAPAVIR SODIUM

    US Patent Number : 10071985

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 215973

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2037-08-17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    AES 2024
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2041-06-04

    LENACAPAVIR SODIUM

    US Patent Number : 11944611

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 215974

    Patent Use Code : U-3507

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2041-06-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    AES 2024
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2037-08-17

    LENACAPAVIR SODIUM

    US Patent Number : 10071985

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 215974

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2037-08-17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    AES 2024
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2041-06-04

    LENACAPAVIR SODIUM

    US Patent Number : 11944611

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 215973

    Patent Use Code : U-3507

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2041-06-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    AES 2024
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2038-08-16

    LENACAPAVIR SODIUM

    US Patent Number : 11267799

    Drug Substance Claim : Y

    Drug Product Claim :

    Application Number : 215973

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2038-08-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    AES 2024
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2037-08-17

    LENACAPAVIR SODIUM

    US Patent Number : 10654827

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 215973

    Patent Use Code : U-3507

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2037-08-17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    US Exclusivities

    read-more
    read-more

    GILEAD SCIENCES INC

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    LENACAPAVIR SODIUM

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    NCE
    2027-12-22
    215974
    1
    blank

    01

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    Antibody Engineering
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    LENACAPAVIR SODIUM

    Exclusivity Code : NCE

    Exclusivity Expiration Date : 2027-12-22

    Application Number : 215974

    Product Number : 1

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    GILEAD SCIENCES INC

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    LENACAPAVIR SODIUM

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    NCE
    2027-12-22
    215973
    1
    blank

    02

    GILEAD SCIENCES INC

    LENACAPAVIR SODIUM

    arrow
    Antibody Engineering
    Not Confirmed

    GILEAD SCIENCES INC

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    LENACAPAVIR SODIUM

    Exclusivity Code : NCE

    Exclusivity Expiration Date : 2027-12-22

    Application Number : 215973

    Product Number : 1

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search